|
|
Cdc42表达载体构建及协同药物对细胞迁移的影响
|
Abstract:
为了研究Cdc42协同拟肽化合物对A549细胞迁移的影响，构建携带红、绿荧光报告基因的Cdc42真核表达载体，转染293T细胞，观察基因表达情况；测定实验用化合物(PMC4)对A549细胞的毒性；进一步将Cdc42转染高迁移率的A549细胞，然后用拟肽化合物刺激，通过细胞划痕实验，初步检测Cdc42协同拟肽化合物对A549细胞迁移的影响。结果表明：本实验成功构建了Cdc42异构体基因的真核表达载体pGFP-cdc42-2、pGFP-cdc42-3、pRed-cdc42-2、pRed-cdc42-3，转染293T细胞效率约为90%；10 μmol/L的拟肽化合物对A549细胞毒性微弱，拟肽药物分子末端对位上的取代基为氟时，其对细胞迁移具有促进作用，过表达Cdc42时，Cdc42协同药物使细胞迁移进一步增加，具体机制有待进一步研究。
In order to study the effect of Cdc42 coordinating with the peptidomimetics on the migration of A549 cells, the Cdc42 eukaryotic expression vectors harboring fluorescent reporter genes were constructed and transfected into 293T cells. The expression of Cdc42 was observed by fluorescence microscopy. The cytotoxicity of the compound (PMC4) on A549 cells was tested. The Cdc42 genes were further ex- pressed in the high mobility cells A549 and the compound was added. The cooperation effect of Cdc42 with the compound on the cell migration was investigated by cell wound scratch assay. The results showed that the eukaryotic expression vectors of Cdc42 isoform genes were successfully constructed named pGFP-cdc42-2, pGFP-cdc42-3, pRed-cdc42-2, pRed-cdc42-3 respectively. These recombinants plasmids were transfected into 293T cells and the transfection ef-ficiency was about 90%. 10 μmol/L peptidomimetic compounds showed weak toxicity to A549 cells. When the substituent group at the terminal para-position of the peptidomimetic drug molecule is F (fluorin), it can increase the migration of A549 cells. While the Cdc42 gene was over-expressed in A549 cells and the cell migration rate was enhanced furtherly. More studies and results need to be carried out to reveal the detail mechanism.
| [1] | Maldonado, M.D.M., Medina, J.I., Velazquez, L., et al. (2020) Targeting Rac and Cdc42 GEFs in Metastatic Cancer. Frontiers in Cell and Developmental Biology, 8, 201. https://doi.org/10.3389/fcell.2020.00201 |
| [2] | Melendez, J., Grogg, M. and Zheng, Y. (2011) Signaling Role of Cdc42 in Regulating Mammalian Physiology. The Journal of Biological Chemistry, 286, 2375-2381. https://doi.org/10.1074/jbc.R110.200329 |
| [3] | Stengel, K. and Zheng, Y. (2011) Cdc42 in Oncogenic Transformation, Invasion, and Tumorigenesis. Bone, 23, 1415-1423. https://doi.org/10.1016/j.cellsig.2011.04.001 |
| [4] | Sinha, S. and Yang, W. (2008) Cellular Signaling for Activation of Rho GTPase Cdc42. Cell Signal, 20, 1927-1934.
https://doi.org/10.1016/j.cellsig.2008.05.002 |
| [5] | Xiao, X.H., Lv, L.C., Duan, J., et al. (2018) Regulating Cdc42 and Its Signaling Pathways in Cancer: Small Molecules and MicroRNA as New Treatment Candidates. Molecules, 23, 787-808. https://doi.org/10.3390/molecules23040787 |
| [6] | Zhang, Y., Li, J., Lai, X.N., et al. (2019) Focus on Cdc42 in Breast Cancer: New Insights, Target Therapy Development and Non-Coding RNAs. Cells, 8, 146. https://doi.org/10.3390/cells8020146 |
| [7] | Aspenstr？m, P. (2018) Activated Rho GTPases in Cancer—The Beginning of a New Paradigm. International Journal of Molecular Sciences, 19, 3949. https://doi.org/10.3390/ijms19123949 |
| [8] | Svensmark, J.H. and Brakebusch, C. (2019) Rho GTPases in Cancer: Friend or Foe? Oncogene, 38, 7447-7456.
https://doi.org/10.1038/s41388-019-0963-7 |
| [9] | Porazinski, S., Parkin, A. and Pajic, M. (2020) Rho-ROCK Signaling in Normal Physiology and as a Key Player in Shaping the Tumor Microenvironment. Advances in Experimental Medicine and Biology, 1223, 99-127.
https://doi.org/10.1007/978-3-030-35582-1_6 |
| [10] | Zhang, M., Guo, W., Qian, J., et al. (2016) Negative Regulation of Cdc42 Expression and Cell Cycle Progression by miR-29A in Breast Cancer. Open Medicine, 11, 78-82. https://doi.org/10.1515/med-2016-0015 |
| [11] | Kharbanda, S., Saxena, S., Yoshida, K., et al. (2000) Translocation of SAPK/JNK to Mitochondria and Interaction with Bcl-x(L) in Response to DNA Damage. Journal of Biological Chemistry, 275, 322-327.
https://doi.org/10.1074/jbc.275.1.322 |
| [12] | Schreiber, M., Kolbus, A., Piu, F., et al. (1999) Control of Cell Cycle Progression by c-Jun Is p53 Dependent. Genes & Development, 13, 607-619. https://doi.org/10.1101/gad.13.5.607 |
| [13] | Zhang, Y., Jiang, L., Qu, X.C., et al. (2010) Expression of Cdc42 in Adriamycin-Sensitivity and Adriamycin-Resistance MCF-7 Human Breast Cancer Cell Line. Chinese Journal of General Surgery, 19, 493-496. |
| [14] | Schiff, R., Massarweh, S.A., Shou, J., et al.(2004) Cross-Talk between Estrogen Receptor and Growth Factor Pathways as a Molecular Target for Overcoming Endocrine Resistance. Clinical Cancer Research, 10, 331s-336s.
https://doi.org/10.1158/1078-0432.CCR-031212 |
| [15] | Azios, N.G., Krishnamoorthy, L., Harris, M., et al. (2007) Estrogen and Resveratrol Regulate Rac and Cdc42 Signaling to the Actin Cytoskeleton of Metastatic Breast Cancer Cells. Neoplasia, 9, 147-158. https://doi.org/10.1593/neo.06778 |
| [16] | Gao, Y., Xing, J., Streuli, M., et al. (2001) Trp(56) of rac1 Specifies Interaction with a Subset of Guanine Nucleotide Exchange Factors. Journal of Biological Chemistry, 276, 47530-47541. https://doi.org/10.1074/jbc.M108865200 |
| [17] | Humphries-Bickley, T., Castillo-Pichardo, L., Hernandez-O’Farrill, E., et al. (2017) Characterization of a Dual Rac/Cdc42 Inhibitor MBQ-167 in Metastatic Cancer. Molecular Cancer Therapeutics, 16, 805-818.
https://doi.org/10.1158/1535-7163.MCT-16-0442 |
| [18] | Frost, J.A., Swantek, J.L., Stippec, S., et al. (2000) Stimulation of NFkappa B Activity by Multiple Signaling Pathways Requires PAK1. Journal of Biological Chemistry, 275, 19693-19699. https://doi.org/10.1074/jbc.M909860199 |
| [19] | 涂国刚, 李少华, 黄惠明, 等. 小分子拟肽类氨肽酶N抑制剂的合成及初步活性[J]. 中国药物化学杂志, 2008(5): 345-349. |
